Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (522)	4/6/1999 2:30:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

from the Ariad website... ARIAD is pursuing a series of related patent applications on NF-kB, to which it holds an exclusive license. corporate-ir.net From Nature Medicine...a new abstact regarding NF-kB (abstract is accessible from the website without subscription, so I will re-post it here) April 1999 Volume 5 Number 4 pp 412 - 417 Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-B Cun-Yu Wang1, 2, 3, James C. Cusack1, 4, Rong Liu1 & Albert S. Baldwin1, 3, 5 Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-oncogenic therapies such as chemotherapy and radiation effect their responses. Resistance to apoptosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these cancer therapies. The transcription factor NF-B is activated by chemotherapy and by irradiation in some cancer cell lines. Furthermore, inhibition of NF-B in vitro leads to enhanced apoptosis in response to a variety of different stimuli. We show here that inhibition of NF-B through the adenoviral delivery of a modified form of IB, the inhibitor of NF-B, sensitizes chemoresistant tumors to the apoptotic potential of TNF and of the chemotherapeutic compound CPT-11, resulting in tumor regression. These results demonstrate that the activation of NF-B in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish the inhibition of NF-B as a new approach to adjuvant therapy in cancer treatment. 1. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box 7295, North Carolina 27599-7295, USA 2. Department of Endodontics, School of Dentistry,University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA 3. Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA 4. Department of Surgery, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA 5. Department of Biology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA C.-Y.W. & J.C.C. contributed equally to the study Correspondence should be addressed to A S Baldwin. also news-observer.com Thanks to Rick who posted that url on another thread... Would be nice to see some PR from Ariad...has not been one of my best investments...I have a little stock since $2...and not too happy that I got into the warrants obviously. --Mike

To: Dr. John M. de Castro who wrote (522)	4/23/1999 12:18:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

I know I get a little repetitive, and this one is a bit off topic, being a neuro article an all, but what the heck--the paper is a very easy read for those of us who are newbies to biotech, so I'll post it. Possible role of NF-kB and p53 in the glutamate -induced pro-apoptotic neuronal pathway stockton-press.co.uk that's the url to Adobe PDF, go here for the abstract stockton-press.co.uk I know there are a whole gaggle of transciption factors, but this one seems to keep coming up here and there. Oh, did I mention this;-) ARIAD is pursuing a series of related patent applications on NF-kB, to which it holds an exclusive license.